A dosage of 1 g of valacyclovir 3 times per day (TID) for 7 days has already been shown to be superior to an oral dosage of 800 mg acyclovir 5 times per day for 7 days in immunocompetent individuals. The objective of this study was to assess the safety and efficacy of an oral dosage of valacyclovir, 1 g TID versus 2 g TID, for the treatment of herpes zoster in immunocompromised patients 18 years of age. The oral dosage schedule of 2 g of valacyclovir TID reaches acyclovir plasma levels similar to those achieved with intravenous acyclovir therapy given to immunocompromised patients (10 mg/kg every 8 h for 7 days). In this double-blind study, 87 immunocompromised patients with clinical evidence of localized herpes zoster were randomized to receive oral valacyclovir therapy for 7 days, either 1 g TID or 2 g TID, within 72 h after onset of zoster rash. Patients were seen and assessed for cutaneous healing, zoster-associated pain (ZAP), and/or zoster-associated abnormal sensations (ZAAS), up to 24 weeks. Participants in both arms of the study demonstrated similar median times to full crusting of the rash (8 days), and both dosages were safe and effective therapies for reduction of ZAP and ZAAS in the immunocompromised patient population.
Trials registration. ClinicalTrials.gov identifier: NCT00006131.
Herpes zoster, or shingles, is a common disease caused by a reactivation of the varicella-zoster virus (VZV). Subsequent to primary VZV infection (i.e., chickenpox), the virus lies latent in the dorsal root ganglia, and reactivation can occur at any age [1, 2] . Yet the incidence and severity of the disease and the prevalence of zoster-associated pain, the most frequent cause of morbidity, increases with age [3, 4] . The increased propensity for VZV reactivation (her-pes zoster) and its complications in the elderly is thought to be related to declining cellular immunity [5, 6] . In the immunocompromised host, VZV reactivation can be particularly severe, with significant morbidity and mortality [7] . The incidence of herpes zoster is 20-to 100-fold higher in immunosuppressed patients, compared with immunocompetent patients, and the severity of the disease among immunocompromised patients has also increased [8] .
In otherwise healthy adults, herpes zoster usually presents as a discrete, unilateral rash, that affects 1-3 adjacent dermatomes, often accompanied or preceded by pain. The erythematous maculopapular rash generally progresses to vesicles or blisters, which then crust or scab before healing. Dissemination of VZV, which is more common in immunocompromised patients, may lead to potentially fatal complications, such as pneumonia, hepatitis, or encephalitis.
The most frequent complication of herpes zoster is chronic zoster-associated pain, which is often referred to as postherpetic neuralgia (PHN). This pain, which affects approximately 40% of patients over the age of 50, can persist for months or even years after the acute episode [1, 3, 4, 9, 10] . Other neurological complications of herpes zoster infection include motor paralysis resulting in facial palsy, temporary muscle paralysis, or bladder and/or bowel dysfunction [11] . Patients in whom the ophthalmic division of the trigeminal nerve is affected are at risk of developing intraocular complications such as keratitis, uveitis, or scleritis [12] .
Acyclovir has been extensively studied as treatment for VZV infection in the immunocompromised host. This group of patients with herpes zoster may be treated with oral acyclovir therapy (800 mg taken orally 5 times per day) or with intravenous acyclovir (10 mg/kg of body weight every 8 h), for 7-10 days. Compared with vidarabine therapy, intravenous (IV) acyclovir therapy has been shown to reduce the incidence of cutaneous and visceral virus dissemination and to reduce treatment failures among patients with zoster [13, 14] . Oral acyclovir therapy has displayed similar results, but its low bioavailability of 15% requires the frequent administration of high doses to maintain adequate plasma concentrations.
Valacyclovir, the prodrug of acyclovir, has a 3-fold to 5-fold increase in bioavailability, compared with acyclovir, which allows less frequent administration [15] . In a double-blind, multicenter trial that involved immunocompetent patients with herpes zoster, valacyclovir (1 g 3 times per day [TID] for 7 days) demonstrated superior efficacy for zoster-associated pain, reduced prevalence of pain at 6 months, and was equally safe when compared to acyclovir [15] . However, valacyclovir has not been studied for the treatment of herpes zoster in immunocompromised adults. The plasma concentration of acyclovir that results from oral administration of 2 g of valacyclovir TID approaches that seen after intravenous acyclovir therapy (10 mg/kg every 8 h for 7 days) [16] . Thus, the higher plasma levels of acyclovir resulting from oral valacyclovir therapy may provide the efficacy of IV acyclovir therapy with the convenience of outpatient therapy.
METHODS

Trial design and patient population.
This study was a randomized, double-blind, controlled trial that compared the efficacy and safety of 2 dosages of valacyclovir hydrochloride, 1 g TID and 2 g TID for 7 days, for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. The patients included in this study were male or female individuals 18 years of age with a clinical diagnosis of uncomplicated herpes zoster presenting within 72 h after the onset of rash. To be included in the study, patients had to have immune dysfunction comprised of congenital immune deficiency, active internal malignancy of any type, collagen vascular diseases, organ or bone marrow transplantation, and/or known infection with HIV, or be known to have received cytotoxic drugs or immunosuppressive therapy in the previous 3 months. The patients selected for the study signed a written informed consent form and were willing and able to comply with the requirements of the study.
Patients were excluded from the study for the following reasons: (1) evidence of cutaneous or visceral dissemination of herpes zoster infection (cutaneous dissemination was defined as 20 discrete lesions outside adjacent dermatomes); (2) receipt of topical or systemic anti-VZV medications in the previous 4 weeks; (3) impaired renal function; or (4) abnormal liver function test results; and/or (5) a history of intolerance or hypersensitivity to acyclovir, penciclovir, valacyclovir hydrochloride, or famciclovir. Sexually active women who were able to bear children and postmenopausal women for whom it had been Ͻ1 year since last menses who were not employing adequate contraception were also excluded, as were pregnant and nursing mothers and severely immunocompromised patients, such as HIVpositive patients with CD4 counts Ͻ50 cells/mm 3 and bone marrow, liver, or heart transplantation patients within 9 months after transplantation. While patients were enrolled in the study, they were not allowed to receive the following concurrent treatments: systemic agents with anti-VZV activity from enrollment to day 10 of the study and probenecid from 24 h before the first dose until day 10 of the study.
Trial procedures. The duration of the study was 24 weeks because most patients who receive antiviral therapy will cease to experience the complications of zoster by week 24 [17] . The study period was 1.5 years, the time when the last patient enrolled had completed the study. Patients were evaluated for pain, abnormal sensations, and zoster complications. Safety was assessed by the clinician, through monitoring clinical chemistry and hematology values, and by the subjects reporting adverse events (AEs).
Each patient was seen on days 1, 3, 6, 8, 10, 14, 21, and 28 and then every 4 weeks up to and including week 24. The presence or absence of pain, burning, and other types of discomfort or abnormal sensation associated with zoster were evaluated at each study assessment. Patients were asked to grade the intensity of their pain, as an average since their last clinic visit, on a scale that consisted of no pain, just noticeable, mild, moderate, severe, or very severe pain. On day 1, patients were asked just to rate their pain on presentation.
On day 1, the clinician assessed rash severity for all patients as mild (Ͻ25 lesions), moderate (25-50 lesions), or severe (Ͼ50 lesions). All patients were also assessed for evidence of dissemination on the basis of the number of noncontiguous lesions outside the adjacent dermatomes. If a patient experienced a recurrence of rash during the 24-week follow-up period, a diagnosis of herpes simplex (HSV) infection was excluded by viral culture. The rest of the patients did not have a viral culture performed because HZ does not typically recur, as HSV does. If the recurrence involved the same dermatome as the initial infection, the patient was excluded from the efficacy subset for all analyses. In addition, all patients were evaluated for the development and resolution of any zoster-associated complications, such as bacterial infection, other cutaneous manifestations, or motor neuropathy. Pregnancy tests were performed during the screening visit on all female patients who were able to bear children, and the result was obtained prior to enrollment in the study.
We defined an AE as any undesirable medical event that the patient encountered during the trial, regardless of whether it was related to the study drug. All AEs that occurred during the period from the initiation of therapy to day 10 were recorded in the case report form, regardless of their association with the study drug. From day 11 until the end of week 24, only serious adverse events (SAEs) were recorded in the case report form and only if there was a reasonable possibility that the SAE was attributable to the study drug. Abnormal lab values were followed until values returned to baseline.
Efficacy end points. The primary efficacy end point was the time to complete cessation of zoster-associated pain (ZAP). The secondary efficacy end points were the time to cessation of zoster-associated abnormal sensation (ZAAS), assessed at the time of the visit; percentage of days 1-28 with ZAP and/or ZAAS; percentage of weeks 1-24 with ZAP and/or ZAAS; days to complete healing of zoster-associated rash; and percentage of patients with zoster-associated complications.
Statistical methods. The sample size was based on pragmatic considerations, rather than power to detect a given difference. We planned to enroll at least 66 patients so that 25 patients would complete therapy and follow-up in each treatment group (for a total of 50 patients who completed the study).
The intent-to-treat population was defined as the patients randomized to treatment who returned to the clinic for at least 1 evaluation after the initiation of treatment. The safety population was defined as the patients randomized to treatment who took at least one dose of study medication. The per-protocol population excluded patients who had major protocol violations, which were defined as patients not meeting study enrollment criteria, returning more than 20% of study medication, discontinuing study medication within 5 days of initiating treatment, failure to start treatment within 72 h after rash onset, and absence of rash assessments.
The principal populations were the intent-to-treat population for efficacy end points and the safety population for safety end points. Per-protocol analyses were also performed for the primary efficacy end point, time to complete cessation of ZAP. Complete cessation of ZAP required confirmation with a 28-day pain-free period after which there were no further reports of pain. Patients for whom cessation of pain was not confirmed were censored at the last day of reported pain. The distribution of this end point was estimated using the Kaplan-Meier product-limit survival method. Differences between the treatment groups were assessed using the Cox proportional hazards model after adjusting for age, sex, presence of prodromal pain, pain severity at baseline, rash severity at baseline, and time between rash onset and start of treatment. Time to complete cessation of abnormal sensation was handled in a similar fashion, although tests of treatment difference were not planned for this or other secondary end points. Secondary efficacy end points were analyzed by use of descriptive statistics.
RESULTS
Study population characteristics.
Of 87 patients enrolled (45 of whom received 1 g TID and 42 of whom received 2 g TID), 63 completed the study. All 87 patients enrolled were included in an intent-to-treat analysis. The most common reason for not completing the study was loss to follow-up (47% of patients). Demographic characteristics and baseline data are summarized in table 1. The majority of patients were white (76%), and just over half were female (54%). There was generally a good balance between the 2 treatment groups, although a greater proportion of patients in the 2 g arm initiated treatment within 48 h (80%), compared with the 1 g arm (62%). This difference was not statistically significant (P ϭ .07). During the 24 week follow-up, there was no evidence of reactivation of herpes zoster in any of the study patients.
Of 87 patients, 31 (35%) had solid organ cancer and were undergoing treatment with chemotherapy and/or radiation therapy. A total of 20 patients (22%) had HIV infection, 15 (17%) had lymphoma, and another 14 (16%) had autoimmune disease. Three (3%) had pulmonary disease and were receiving immunosuppressive medications; 2 (2%) had undergone solid organ transplantation. One patient (1%) had solid organ cancer in addition to autoimmune disease, and there was 1 (1%) subject with multiple myeloma.
Time to cessation of zoster-associated pain. Table 2 displays the results of the multivariate analysis of the time to cessation of ZAP, and figure 1 displays the Kaplan-Meier analysis. Although the 2 g arm was associated with shorter duration of ZAP, compared to the 1 g arm, with a hazard ratio (HR) of 1.279, this difference was not statistically significant (P ϭ .44). Among the covariates included in the multivariate model, baseline rash severity alone was statistically significant (P ϭ .03); patients who had mild rash had a shorter duration of zoster-associated pain (HR, 0.440).
Secondary efficacy end points. Table 2 also displays the results of the multivariate analysis of the time to cessation of ZAAS (defined as localized anesthesia, hyperesthesia, or pruritus) and figure 1 displays the Kaplan-Meier analysis. The 2 treatment arms are superimposable in the graph. As measured by the time to cessation of ZAAS, patients who had mild rash had a shorter duration of ZAAS.
Based on a descriptive analysis of data collected during the period from days 1-28 after initiation of treatment, patients in the 1 g TID treatment arm had a higher mean percentage of total days affected by ZAP than those in the 2 g TID arm (85% vs. 76%) (table 3) , whereas the percentage of days affected by ZAAS was higher for patients in the 2 g TID group, compared to those in the 1 g TID group (66% vs. 58%). Examination of the number of study-weeks affected by ZAP revealed a higher percentage of weeks affected for patients in the 1 g treatment arm, compared with those in the 2 g treatment arm. The number of weeks affected by ZAAS was similar for both arms of the study, and they were similar in quality. There was no substantial difference between treatment groups in the time from treatment initiation to full crusting; median times to healing were 8 days in both groups. Zoster-associated complications were experienced by 2 patients (4%) in the 1 g TID group and 3 patients (7%) in the 2 g TID group. The distribution of patient median ratings for severity of ZAP was similar for the 2 treatment groups; 13% of patients in each treatment group (i.e., 6 patients in the 1 g TID group and 5 patients in the 2 g TID group) reported that their median pain rating was severe or very severe (table 4) . Safety. AEs were intensively collected for the first 10 days of the study. Afterward, only SAEs possibly attributed to the study drug were reported. AEs were reported by 22 patients (49%) in the 1 g treatment arm and by 25 patients (60%) in the 2 g treatment arm. Drug-related AEs were reported by 6 patients (13%) in the 1 g treatment arm and in 6 patients (14%) in the 2 g treatment arm. The most common drug-related AEs included headache, pain, nausea, vomiting, and constipation. There were no treatment-limiting events.
SAEs were reported by 19 patients (6 in the 1 g treatment arm and 12 in the 2 g treatment arm) in the study. Three of them led to withdrawal of the patient from the study. Five patients (2 in the 1 g TID arm and 3 in the 2 g TID arm) died during the study. All the events associated with death were considered by the investigators to be unrelated to the study medication. Deaths either were attributed to the patient's underlying medical condition or were considered to be due to unknown cause.
Laboratory assessments. Clinically significant changes from the baseline chemistry and hematology profiles were observed in subjects from both arms of the study. These included hyponatremia (in a patient with brain cancer), anemia (in patients with myelodysplastic syndrome and prostate cancer), thrombocytosis and anemia (in a patient with systemic lupus erythematosus), elevated transaminases (in a patient with chronic hepatitis) , high white cell and/or neutrophil count (in a patient with scleroderma who was recovering from upper respiratory infection). These changes were considered unrelated to the study drug.
DISCUSSION
This randomized, double-blind, controlled trial determined that 1 g of valacyclovir TID and 2 g TID of valacyclovir were well tolerated for the treatment of herpes zoster in immunocompromised patients 18 years of age. The Kaplan-Meier plot generated from intent-to-treat analysis of both patient groups showed a downward trend in the persistence of ZAP over time that compared favorably with similar plots from selected prior controlled trials of valacyclovir (in comparison with acyclovir) [15] ; patients in the 2 g TID treatment arm had an accelerated resolution, compared with those in the 1 g TID treatment arm. Both populations showed similar downward trends for ZAAS.
A prior study, which involved 148 patients, that examined treatment of herpes zoster among immunocompromised patients with oral famciclovir therapy (500 mg TID), compared with oral acyclovir therapy (800 mg 5 times per day), demonstrated famciclovir to be clinically and statistically equivalent to acyclovir. The median time to full crusting was 8 days for fam- ciclovir recipients and 9 days for acyclovir recipients [7] . In our study, the median time to full crusting of all lesions was 8 days for both the 2 g TID and 1 g TID treatment arm. Another trial that compared IV acyclovir therapy and vidarabine for the treatment of herpes zoster in 22 severely immunocompromised patients demonstrated that the median time to full crusting was 7 days for IV acyclovir therapy [14] , which is only slightly better than results of our trial with oral valacyclovir therapy. In a study [18] that was done to determine the success of outpatient IV acyclovir therapy for immunosuppressed patients with cancer, patients expressed a high level of satisfaction of being treated in an ambulatory and/or home setting. Parenterally administered acyclovir in an ambulatory setting was an effective therapy in this study, with most patients (87%) responding to treatment. Seven patients (18%) had to be switched to oral acyclovir therapy, 800 mg 5 times a day, before complete response because of venous access problems.
The safety and tolerability of valacyclovir have already been evaluated in immunocompetent patients with herpes zoster [15] . The incidence and profile of commonly occurring AEs in the immunocompromised population enrolled in our study were similar between the 2 arms of the study. Commonly occurring events were consistent with those observed in the immunocompetent patients (e.g., nausea, headache, and vomiting); underlying conditions in this immunocompromised patient population may have contributed to the SAEs that occurred. There were no reports of thrombotic thrombocytopenic purpura or hemolytic uremic syndrome. This syndrome, which can be fatal, has occurred in patients in the late stages of HIV disease in clinical trials of valacyclovir at high dose of 8 g per day [19] . Further, there were no patients in our study who developed disseminated zoster.
Outpatient therapy with valacyclovir for immunocompromised patients is markedly cost-effective. One gram of valacyclovir TID costs approximately $250 for 7 days, which means that the 2 g TID cost is $500; in the study mentioned above [18] , the cost of outpatient acyclovir therapy was approximately $1433 per day, compared with $2228 per day for inpatients receiving IV acyclovir therapy.
In summary, the results of our study have demonstrated the various benefits of both 1 g and 2 g of valacyclovir TID for immunocompromised patients with herpes zoster. The 1 g TID dosage of valacyclovir resulted in a complete healing time similar to that of the 2 g TID dosage, which suggests that the lower dosage treatment would be more cost-effective while still retain-ing efficacy. Further studies with immunocompromised patients are needed to confirm these findings.
